<DOC>
	<DOCNO>NCT00840086</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , North South America . The trial consist main trial sub-trial . The main trial investigates safety efficacy turoctocog alfa ( recombinant factor VIII , rFVIII ( N8 ) ) haemophilia A subject , sub-trial investigates safety efficacy turoctocog alfa prevention treatment bleed episode surgical procedure .</brief_summary>
	<brief_title>Safety Efficacy Turoctocog Alfa Haemophilia A Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject diagnosis severe ( FVIII le equal 1 % ) haemophilia A age 12 ( except Israel age limit 18 first 10 subject recruit trial ) 56 year weight 10 120 kg Documented history least 150 exposure day FVIII product ( prevention treatment bleeds ) No history FVIII inhibitor great equal 0.6 BU/mL . The inhibitor measure regularly least last 8 year since first treatment haemophilia A No detectable inhibitor FVIII ( great equal 0.6 BU/mL ) ( assessed Central Laboratory time screen ) Congenital acquire coagulation disorder haemophilia A Creatinine level 50 % normal level ( defined central laboratory range ) Known suspect allergy trial product ( N8 ) relate product</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>